Race Oncology Limited (ASX:RAC)
Australia flag Australia · Delayed Price · Currency is AUD
1.200
+0.010 (0.84%)
Jul 25, 2025, 4:10 PM AEST

Race Oncology Company Description

Race Oncology Limited, a clinical stage biopharmaceutical company, focuses on addressing the unmet needs of cancer patients for damaging treatments.

The company’s lead product is bisantrene, a small molecule chemotherapeutic that has a clinical history with demonstrated therapeutic benefits in adult and paediatric patients.

It is advancing reformulated bisantrene (RC220) to address the unmet need of patients across various oncology indications with a clinical focus on anthracycline combination to deliver cardioprotection and enhanced anticancer activity in solid tumors.

The company is also exploring RC220 as a low intensity treatment for acute myeloid leukaemia. In addition, it is investigating the effect of bisantrene on the m6A RNA pathway, following independent research identifying bisantrene as the potent inhibitor of fat mass and obesity-associated protein.

The company has collaborations with Astex, City of Hope, MD Anderson, Sheba City of Health, UNC School of Medicine, University of Wollongong, and University of Newcastle.

The company was formerly known as Coronado Resources Limited. Race Oncology Limited was incorporated in 2011 and is headquartered in Sydney, Australia.

Race Oncology Limited
Race Oncology logo
CountryAustralia
Founded2011
IndustryBiotechnology
SectorHealthcare
CEODaniel Tillett

Contact Details

Address:
Gateway, 1 Macquarie Place
Sydney, 2000
Australia
Phone61 2 8051 3043
Websiteraceoncology.com

Stock Details

Ticker SymbolRAC
ExchangeAustralian Securities Exchange
Fiscal YearJuly - June
Reporting CurrencyAUD
ISIN NumberAU000000RAC3
SIC Code2836

Key Executives

NamePosition
Dr. Daniel TillettChief Executive Officer, Managing Director and Director
Dr. Peter M. Smith Ph.D.Executive Chairman
Brendan BrownChief Financial Officer
Dr. Sophia MoscovisVice President of Operations and Strategy
Dr. Jose L. Iglesias M.D.Chief Medical Officer
Peter Gordon Webse B.Bus, FCIS, FCPA, FGIA, M.A.I.C.D.Company Secretary